Pursuant to the agreement, the Company will receive payments totalling USD 72 million by March 31, 2024. The said agreement resolves all claims between the parties relating to the Company’s generic buprenorphine and naloxone sublingual film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg dosages, including Indivior’s and Aquestive’s patent infringement allegations and the Company’s antitrust counterclaims. As part of the settlement, the underlying litigation will be dismissed.
Shares of Dr. Reddy’s Laboratories Limited was last trading in BSE at ₹4308.75 as compared to the previous close of ₹4296.20. The total number of shares traded during the day was 6881 in over 1656 trades.
The stock last hit in BSE,
- Intraday High of ₹ 4370.00
- Intraday low of ₹ 4292.35